Shares of Affimed (NASDAQ:AFMD - Get Free Report) have received a consensus rating of "Buy" from the four research firms that are covering the firm, Marketbeat.com reports. Four analysts have rated the stock with a buy recommendation. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $20.00.
Several research analysts have recently weighed in on AFMD shares. HC Wainwright reiterated a "buy" rating and set a $10.00 price target on shares of Affimed in a research note on Friday, September 6th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Affimed in a research note on Monday, September 9th.
Get Our Latest Report on AFMD
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Affimed stock. Choreo LLC bought a new position in Affimed (NASDAQ:AFMD - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 10,000 shares of the biopharmaceutical company's stock, valued at approximately $54,000. Choreo LLC owned 0.07% of Affimed as of its most recent SEC filing. Institutional investors own 30.82% of the company's stock.
Affimed Stock Performance
NASDAQ:AFMD traded up $0.04 during trading on Monday, reaching $3.37. The company's stock had a trading volume of 90,248 shares, compared to its average volume of 277,316. The company has a quick ratio of 2.71, a current ratio of 2.71 and a debt-to-equity ratio of 0.13. The firm has a 50 day moving average of $3.66 and a 200-day moving average of $4.69. Affimed has a 12 month low of $2.92 and a 12 month high of $8.95.
Affimed (NASDAQ:AFMD - Get Free Report) last announced its quarterly earnings data on Thursday, September 5th. The biopharmaceutical company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.00) by ($0.09). The business had revenue of $0.17 million during the quarter, compared to the consensus estimate of $1.67 million. Affimed had a negative net margin of 2,922.74% and a negative return on equity of 155.30%. Equities analysts forecast that Affimed will post -4.25 earnings per share for the current year.
About Affimed
(
Get Free ReportAffimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.
See Also
Before you consider Affimed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Affimed wasn't on the list.
While Affimed currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
